If You Invested in Novo-Nordisk A S (NONOF)
Looking for the current price? See the NONOF quote & overviewWhat $1,000 or $10,000 in NONOF Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Dec 31, 2021 |
|---|---|---|---|---|
| $1,000 | $914 -9% | — | — | $901 -10% |
| $10,000 | $9,142 -9% | — | — | $9,007 -10% |
Based on real historical closing prices, dividend- and split-adjusted, through 2026-07-28. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for NONOF$1,000 Investment Over Time
NONOF vs S&P 500Year-by-Year Returns
NONOF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021 | $55.52 | $55.52 | +0.0% | +0.0% |
| 2022 | $54.91 | $68.25 | +24.3% | +22.9% |
| 2023 | $68.00 | $102.50 | +50.7% | +84.6% |
| 2024 | $101.20 | $85.90 | -15.1% | +54.7% |
| 2025 | $87.12 | $51.05 | -41.4% | -8.0% |
| 2026 | $52.74 | $50.00 | -5.2% | -9.9% |
About Novo-Nordisk A S
Healthcare · OTC Link
NOVO NORDISK A/S B NEW (NONOF) represents an interest in Novo Nordisk A/S, a global healthcare company that focuses on serious chronic diseases. According to its SEC filings, Novo Nordisk was founded in 1923 and is headquartered in Denmark. The company highlights a corporate purpose of driving change to defeat serious chronic diseases, building on its heritage in diabetes.
In its regulatory disclosures, Novo Nordisk states that it pursues this purpose by pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure disease. The company reports that it employs tens of thousands of people across numerous countries and markets its products in a large number of markets worldwide. Novo Nordisk's B shares are listed on Nasdaq Copenhagen under the symbol Novo-B, and its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the symbol NVO.
Business focus and therapeutic areas
The SEC filings describe Novo Nordisk as a healthcare company with a heritage in diabetes and a focus on serious chronic diseases. Within that broad focus, the company discloses several key areas of activity:
- Diabetes and type 2 diabetes: Novo Nordisk refers to semaglutide, a GLP-1 receptor agonist marketed under the brand names Ozempic and Rybelsus for the treatment of type 2 diabetes.
- Chronic weight management and obesity: Wegovy is described as a treatment for chronic weight management. The company also reports development programmes and approvals related to weight management in adults with obesity or overweight with weight-related comorbidities.
- Metabolic-associated steatohepatitis (MASH): Wegovy injection is indicated for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
- Type 2 diabetes and obesity pipeline: Novo Nordisk reports development of amycretin, described as a unimolecular, long-acting GLP-1 and amylin receptor agonist under development for adults with overweight or obesity and as a treatment for adults with type 2 diabetes.
Key products and pipeline candidates mentioned in filings
Based on the provided SEC filings, several specific medicines and candidates are highlighted:
- Semaglutide: A GLP-1 receptor agonist marketed under the brand names Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management.
- Wegovy: Described as approved by the U.S. Food and Drug Administration (FDA) as a once-weekly injection for chronic weight management and as a once-daily tablet (Wegovy pill, semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related medical condition. Wegovy is also indicated to reduce the risk of major adverse cardiovascular events in adults with known heart disease and either obesity or overweight, and the injection is indicated for certain paediatric patients and for treatment of MASH in adults with moderate to advanced liver fibrosis.
- Amycretin: A unimolecular agonist of the GLP-1 and amylin receptors under development. Novo Nordisk reports positive phase 2 results in people with type 2 diabetes, including statistically significant weight loss and reductions in HbA1c compared to placebo, and states that amycretin is being developed for both oral and subcutaneous administration.
Research and development activities
The company’s filings describe multiple clinical development programmes:
- OASIS programme: A phase 3 clinical development programme with once-daily oral semaglutide 25 mg and 50 mg in obesity. The filings state that it consists of four trials enrolling approximately 1,300 adults with obesity or overweight with one or more comorbidities, including the OASIS 4 trial, a 64-week efficacy and safety trial comparing oral semaglutide 25 mg to placebo.
- Amycretin phase 2 trial in type 2 diabetes: An interventional, multinational, multi-centre, randomised, parallel, double-blind, placebo-controlled, dose-finding study evaluating once-weekly subcutaneous and once-daily oral amycretin in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. The trial investigates safety, efficacy and pharmacokinetic properties, with primary endpoints focused on HbA1c change and secondary endpoints including changes in body weight.
- Evoke and evoke+ trials in Alzheimer’s disease: Two global, randomised, double-blind, placebo-controlled phase 3 trials evaluating once-daily oral semaglutide 14 mg in early-stage symptomatic Alzheimer’s disease. Novo Nordisk reports that these trials did not demonstrate a statistically significant reduction in disease progression as measured by the Clinical Dementia Rating – Sum of Boxes (CDR-SB) score, and that the extension period will be discontinued based on the efficacy results.
Corporate governance and listings
Several 6-K filings relate to governance and capital markets activity:
- Board composition: An extraordinary general meeting elected new members to the Board of Directors, including a new chair and vice chair, and restructured board committees such as the People and Governance Committee, Remuneration Committee, Audit Committee and Research & Development Committee.
- Insider transactions: The company discloses trading in Novo Nordisk shares by board members, executives and associated persons, in accordance with market abuse regulations. These filings provide details such as the number of shares, price, and trading venue (Nasdaq Copenhagen) for specific transactions.
- Share listings: Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B), and its ADRs are listed on the New York Stock Exchange (NVO), as stated consistently across multiple filings.
Geographic footprint and scale
In multiple filings, Novo Nordisk reports that it employs about 78,400 to 78,500 people in 80 countries and markets its products in around 170 countries. These statements indicate a broad international footprint in terms of both operations and product availability. All of these figures are presented as part of the company’s own disclosures.
NONOF as an investment reference
On Stock Titan, the symbol NONOF is associated with Novo Nordisk A/S B NEW. While the SEC filings provided refer to Novo Nordisk A/S and its B shares on Nasdaq Copenhagen and ADRs on the NYSE, the NONOF ticker gives investors another way to follow information related to Novo Nordisk’s B share class. The filings offer insight into the company’s therapeutic focus, clinical development efforts, governance changes, and insider transactions, which can be relevant to investors researching NONOF.
Frequently asked questions about NOVO NORDISK A/S B NEW (NONOF)
The following FAQs are based solely on information disclosed in the provided SEC filings.
Frequently Asked Questions
Novo-Nordisk A S investment returns
How much would $1,000 invested in Novo-Nordisk A S be worth today?
If you invested $1,000 in Novo-Nordisk A S (NONOF) 1 years ago on 2025-07-29, your investment would be worth $914 as of 2026-07-28, representing a -8.6% total return, growing at a compounded rate of -8.6% per year (CAGR).
Has Novo-Nordisk A S outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare NONOF performance over available time periods.
What is Novo-Nordisk A S's average annual return?
The compound annual growth rate (CAGR) of NONOF over the past 1 years is -8.6%, growing at a compounded rate each year. Individual years vary significantly — NONOF's best recent year was 2023 (+50.7%) and worst was 2025 (-41.4%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
